Directly Observed Therapy in HIV Infected Adolescent Focus Groups

NCT00079729 | Completed

• 2 other identifiers: PACTG P1036A10193
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to help researchers use information from HIV infected adolescents to design a directly observed therapy (DOT) program that will help adolescents take their anti-HIV medications correctly.

Conditions

HIV Infections

Keywords

Treatment Experienced

Eligibility Criteria

• Age: 16 Years - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• HIV infected due to high-risk behavior
• Regular attendee of local adolescent HIV support group
• Current use of antiretrovirals or history of antiretroviral therapy
• Permission of parent or legal guardian if participant is less than the legal age of consent. Assent of the minor participant should be obtained where required.

You may not qualify if:

• Perinatal HIV infection
• Visibly distraught or emotionally unstable
• Pregnancy or breast-feeding

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead
• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): collaborator

Study Sites (3)

Los Angeles County Medical Center/USC

Los Angeles, California, 90033, United States

Location

University of Miami (Pediatric)

Miami, Florida, 33136, United States

Location

St. Jude Childrens Research Hospital, Memphis

Memphis, Tennessee, 38105-2794, United States

Location

Related Publications (5)

• Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M; Adolescent Medicine HIV/AIDS Research Network. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001 Feb;13(1):27-40. doi: 10.1080/09540120020018161.

  PMID: 11177463 BACKGROUND

• Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000 Jul 12;284(2):179-80. doi: 10.1001/jama.284.2.179. No abstract available.

  PMID: 10889588 BACKGROUND

• Lanzafame M, Trevenzoli M, Cattelan AM, Rovere P, Parrinello A. Directly observed therapy in HIV therapy: A realistic perspective? J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):200-1. doi: 10.1097/00042560-200010010-00018. No abstract available.

  PMID: 11103053 BACKGROUND

• Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA. 1999 Oct 13;282(14):1334. doi: 10.1001/jama.282.14.1334. No abstract available.

  PMID: 10527179 BACKGROUND

• Garvie PA, Lawford J, Flynn PM, Gaur AH, Belzer M, McSherry GD, Hu C; Pediatric AIDS Clinical Trials Group 1036A Study Team. Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. J Adolesc Health. 2009 Feb;44(2):124-132. doi: 10.1016/j.jadohealth.2008.05.006. Epub 2008 Oct 18.

  PMID: 19167660 RESULT

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Patricia Flynn, MD

  St. Jude Children's Research Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2004
• First Posted: March 12, 2004
• Study Start: April 1, 2004
• Study Completion: July 1, 2004
• Last Updated: October 29, 2012

Record last verified: 2012-10

Locations

US (3)